BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AEZS-108: Updated Phase II data

Updated data from the open-label, European Phase II AGO-GYN-5 trial in 42 patients with platinum-resistant, LHRH-positive ovarian cancer showed that AEZS-108 produced 5 partial responses and 11 cases of stable disease for >12 weeks. Median time to progression and OS...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >